Pharmaceutical Industry discussion, review, analysis, news and information.

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced that it has received tentative approve for its generic version of Valtrex.

Manufactured by GlaxoKleinSmith, the patent for Valtrex expires in December and final approval for the generic version is expected at that time. Mylan Laboratories Inc. (NYSE:MYL) has also received tentative FDA approval for generic Valtrex. Valtrex is used in the treatment of herpes zoster (shingles), genital herpes and herpes labialis (cold sores).